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INTRODUCTION: Aldosterone levels are elevated in patients with acutely decompensated 
chronic heart failure (ADCHF) despite the use of angiotensin-converting enzyme inhibitors 
(ACEi), angiotensin receptor blockers (ARB), and beta-blockers (BB), and may contribute to 
cardiorenal dysfunction, increasing the risk of death and ventricular arrhythmias. Therefore, 
mineralocorticoid receptor antagonists (MRAs) use in ADCHF treatment has two major 
putative advantages: improve congestion and hypervolemia through its diuretic effect and 
prevent the neurohormonal activation that characterizes ADCHF, and that is enhanced by loop 
diuretics. The impact of MRAs in ADCHF patients has not been studied.   
OBJECTIVES: We aimed to evaluate the short-term clinical effect and safety of the MRA 
antagonist spironolactone in worsening chronic HF patients. 
MATERIAL AND METHODS: Prospective, experimental, single-center, and single-blinded trial. 
Patients were eligible for enrollment if they presented with decompensation of chronic HF 
with symptoms leading to hospitalization. Patients were treated by the assistant physician 
with: standard AHF therapy or oral spironolactone 50 - 100 mg/d plus standard ADCHF 
therapy. An assessment of biomarkers and short-term effects on clinical status and symptoms 
was performed. 
RESULTS: A total of 100 patients were enrolled. Fifty patients were included in the treatment 
group. Mean (SD) spironolactone dose at day 1 was 94,5 ± 23,3 mg and at day 3 was 62,7 ± 
24,3 mg. Patients in the control group were significantly older (mean (SD), 78,8 ± 9,3 vs. 73,2 ± 
11,7 years; p = 0,01). The study groups were well balanced. Greater proportion of patients in 
the treatment group were free of congestion at day 3: no edema (32% vs. 66%; p = 0,001), no 
rales (24% vs. 66%; p < 0,001), jugular venous pressure (JVP) ≤ 8 cm (90% vs. 100%; p = 0,02) 
and no orthopnea (76% vs. 96%; p = 0,004). In addition, a significantly higher proportion of 
patients were on oral furosemide at day 3 (44% vs. 82%; p < 0,001). Worsening renal function 
(increase in pCr ≥ 0,3 mg/dL from day 1 to day 3) was more likely to occur in control group 
(20% vs. 4%; p = 0,038). Serum potassium (K+) levels did not differ significantly between 
groups. Plasma N-terminal pro brain natriuretic peptide (proBNP) had a significant decrease in 
spironolactone group at day 3 (median [IQR], 2488 [4579] vs. 1555 [1832]; p = 0,05).  
CONCLUSIONS: High dose spironolactone in ADCHF is safe, provides faster resolution of 
congestive signs, and reduction of respiratory effort, allowing an earlier switch to oral 
furosemide. These findings were translated into a more pronounced natriuretic peptide 
reduction and lower levels of indirect end-organ damage markers. Our results are a first step 
towards the potential use of this therapy in patients with worsening chronic HF. 
 
